Menu
Exonate
Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.
Drug discovery – wet AMD and cancer
School of Medicine
Profile
Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.
Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.
News and press releases
@ExonateUK on Twitter
Exonate at @aao_ophth American Academy of Opthamology 12-15th October – San Francisco
AAO 2019: Inspire! Is the 123rd annual meeting of the American Academy of Ophthalmology which is the largest exhibition of ophthalmic technology, products and services in the world.
#TBT to last years finalists of @CambridgeIndy #SciTechAwards #OnetoWatch Award. @ANBSensors @CorrosionRADAR @ChirazEnnaceur @CydarMedical @ExonateUK @Fetch_AI @fluidicanalytic @kaliumhealth @Mursla @PhoreMostLtd @Speechmatics @SphereFluidics @StemnovateL https://t.co/bSM61SrPnc
Congratulations to our chairman Sunil Shah on winning Angel investor of the year #UKBAAAwards @UKBAngels
@ExonateUK presented interesting work using splicing to change VEGFA165a (which is pro-angiogenic) to VEGFA165b (which is anti-angiogenic) for #ARMD and #Diabetic macular oedema with an eyedrop EXN407 that is permeable and reaches the retina!
Morning run before the conference with @couloirjunkie in Stanley Park, Vancouver @ARVOinfo #ARVO2019
Prof Bates presenting the latest work from Exonate @ExonateUK @UniofNottingham @MedicineUoN @UoNCancerCentre @JennyBatson
Dr Jennifer Batson is presentating data which outlines preclinical data on Exonate’s lead candidate, EXN407, a specific SRPK1 inhibitor with high retinal bioavailability for the treatment of diabetic macular oedema at (ARVO) today at 8am in Vancouver.
Exonate to present data on lead candidate EXN407 at ARVO 2019, the internationally recognised vision and ophthalmology conference
Exonate
A biopharmaceutical company developing eyedrop treatment for Age Related Macular Degeneration wet AMD using VEGF alternative splicing.
www.exonate.com